Invitae (NYSE: NVTA), a US-based medical genetics company, announced on Monday that it has named Robert Dickey as its new interim chief financial officer (CFO), effective immediately.

Christine Gorjan assumed the role of interim CFO in June 2023. She will move back to her earlier role as the firm's chair of the Audit Committee of the board of directors and member of the Compensation Committee of the board of directors, effective immediately.

Dickey is a finance executive with more than 25 years of experience as a CFO and other C-level and board positions at both private and publicly traded life sciences and medical device companies. He has served for 18 years in investment banking, mostly at Lehman Brothers, with a background divided between M&A and capital markets transactions. He has consulted with more than 10 companies in the life sciences space. Presently, he serves as a member of the board of directors at AngioGenex, SFA Therapeutics and GSNO Therapeutics.